Uso de un antagonista del receptor de vitronectina para la preparacion de una formulacion farmacéutica util para inhibir el exceso de formacion de cicatrices en la piel de a un mamífero en necesidad del mismo por administracion topica. Dicha piel se ha cortado, agrietado, desgarrado o lesionado durante la curacion y la cicatrizacion excesiva puede ser hipertrofica. Dicho antagonista es un compuesto de formula (1) o (2), en la que: R es H, alquilo C1-6, Ar, Het o alquilarilo C1-6; R1 es R7, A- alquiloC0-4, A-alqueniloC2-4, A-alquiniloC2-4, A-oxoalqueniloC3-4, A-oxoalquiniloC3-4, A-aminoalquiloC1-4, A-aminoalqueniloC3-4 o A-aminoalquiniloC3-4, sin sustituir o sustituido con cualquier combinacion posible de uno o más de R10 o R7; A es H, cicloalquilo C3-6, Het o Ar; R7 es -COR8, -COCR'2R9, -C(S)R8, -S(O)mOR', -S(O)mNR'R'', -PO(OR'), -PO(OR')2, -NO2, o tetrazolilo; cada R8 es independientemente -OR', -NR'R'' -NR'SO2R', -NR'OR' o -OCR'2CO(O)R'; R9 es -OR', -CN, -S(O)rR', -S(O)mN(R')2, -C(O)R', C(O)N(R)2 o -CO2R'; R10 es H, halo, -OR11, -CN, -NR'R11 , -NO2, -CF3, CF3S(O)r-, CO2R', -CON(R')2, A-alquiloC0-6-, A-oxoalquiloC1-6-, A-alqueniloC2-6-, A-alquiniloC2-6-, A-alquiloxiC0-6-, A-alquilaminoC0-6- o A-alquilC0-6-S(O)r-; R11es R', - C(O)R', -C(O)N(R')2, -C(O)OR', -S(O)mR' o -S(O)mN(R')2; R2 es un grupo de formulas (3), W es -(CHRg)a-U-(CHRg)b-; U es ausente o es CO, CRg2, C(=CRg2), S(O)k, O, NRg, CRgORg, CRg(ORk)CRg2, CRg2CRg(ORk), C(O)CRg2, CRg2C(O), CONRi, NRiCO, OC(O), C(O)O, C(S)O, OC(S), C(S)NRg, NRgC(S), S(O)2NRg, NRgS(O)2, N=N, NRgNRg, NRgCRg2, CRg2NRg, CRg2O, OCRg2, C:::C o CRg=CRg; G es NRe, S u O; Rg is H, alquilo C1-6, Het-alquiloC0-6, cicloalquilC3-7-alquiloC0-6 o Ar-alquiloC0-6; Rk es Rg, -C(O)Rg, o - C(O)ORf; Ri es H, alquilo C1-6, Het-alquiloC0-6, cicloalquilC3-7-alquiloC0-6, Ar-alquiloC0-6 o alquilo C1-6 sustituido con uno a tres grupos seleccionados entre el grupo que cosiste en halogeno, CN, NRg2, ORg, SRg, CO2Rg, y CON(Rg)2; Rf es H, alquilo C1-6 o Ar-alquiloC0-6; Re es H, alquilo C1-6, Ar-alquiloC0-6, Het-alquiloC0-6, cicloalquilC3-7-alquiloC0-6 o (CH2)kCO2Rg; Rb y Rc se seleccionan independientemente entre el grupo que consiste en H, alquilo C1-6, Ar-alquiloC0-6, Het-alquiloC0- 6, cicloalquilC3-6-alquiloC0-6, halogeno, CF3, ORf, S(O)kRf, CORf, NO2, N(Rf)2, CO(NRf)2, y CH2N(Rf)2, o Rb y Rc se unen para formar un anillo carbocíclico o heterocíclico, aromático o no aromático de cinco o seis miembros, sin sustituir o sustituido con hasta tres sustituyentes seleccionados entre el grupo que consiste en halogeno, CF3, alquilo C1-4, ORf, S(O)kRf, CORf, CO2Rf, OH, NO2, N(Rf)2, CO(NRf)2, CH2N(Rf)2, y metilenodioxi; Q1, Q2, Q3 y Q4 son independientemente N o C-Ry, con la condicion de que no más de Q1, Q2, Q3 y Q4 sea N; R' es H, alquilo C1-6, Ar-alquiloC0-6 o cicloalquilC3-6-alquiloC0-6; R'' es R', -C(O)R' o -C(O)OR'; R''' es H, alquilo C1-6, Ar-alquiloC0-6, Het-alquiloC0-6, cicloalquilC3-6-alquiloC0-6, halogeno, CF3, ORf, S(O)kRf, CORf, NO2, N(Rf)2, CO(NRf)2, o CH2N(Rf)2; Ry es H, halo, -OR9, -SRg, -CN, -NRgRk, -NO2, -CF3, CF3S(O)r-, CO2Rg, -COR9 o -CONRg2, o alquilo C1-6 sin sustituir o sustituido con halo, -ORg, -SRg, - CN, -NRgR'', -NO2, -CF3, R'S(O)r-, - CO2Rg, -CORg o -CONRg2; a es 0, 1 o 2; b es 0, 1 o 2; k es 0, 1 o 2; m es 1 o 2; r es 0, 1 o 2; s es 0, 1 o 2; u es 0 o 1; y v es 0 o 1; o un compuesto de formula (2), en la que A1 es C o N; E es un anillo heteroaromático de cinco o seis miembros o un anillo aromático de seis miembros sin sustituir o sustituido con R3* o R4*; X1-X2 es CHR1*-CH, CR1*=C, NR1*-CH, S(O)u*-CH o O-CH; X3 es CR5*R5'*, NR5*, S(O)u* u O; R* es H, alquilo C1-6, Ar, Het, alquilarilo C1-6; R''* es R'*, -C(O)R'* o - C(O)OR5*; R'''* es alquilo C1-6, cicloalquilC3-7-alquiloC0-4 o Ar-alquiloC0-4; R1* es H, alquilo C1-6, ciclalquilC3-7-alquiloC0-4 o Ar-alquiloC0-4; R2* es -OR'*, -NR'*R''*, -NR'*SO2R'''*, -NROR'*, -OC(R'*)2C(O)OR'*, -OC(R'*)2OC(O)-R'*, - OC(R'*)2C(O)N(R'*)2, CF3 o COC(R'*)2R2'*; R2'* es -OR'*, -CN, -S(O)r*R'*, S(O)2N(R'*)2, -C(O)R'*, C(O)N(R'*)2 o -CO2R'*; R5* y R5'* son independientemente H, alquilo C1-6, cicloalquilC3-7-alquiloC0-4 o Ar-alquiloC0-4; R6* es W-(C(R'*)2)q*-Z*- (CR'*R10*)r*-U*-(C(R'*)2)s*-V*- o W'*-(C(R'*)2)q*-U*-(C(R'*)2)s*-; R3*, R4* y R7* son independientemente H, halo, -OR12*, -SR12*. -CN, -NR'*R12*, -NO2, -CF3, CF3S(O)r*-, -CO2R'*, -CON(R1*)2, R14*-alquiloC0-6-, R14*-oxoalquiloC1-6, , R14*-alqueniloC2- 6-, R14*-alquiniloC2-6, R14*-alquiloxiC0-6-, R14*-CalquilaminoC0-6 o R14*-alquilC0-6-S(O)r*-; R8* es R'*, C(O)R'*, CN, NO2, SO2R'* o C(O)OR5*; R9* es R'*, -CF3, -SR'*, o -OR'*; R1O* es H, alquilo C1-4, o -NR'*R''*; R12* es R'*, -C(O)R'*, - C(O)N(R'*)2, -C(O)OR5*, -S(O)m*R'* o S(O)2N(R'*)2; R14* es H, cicloalquilo C3-6, Het o Ar; R15* es H, alquilo C1-10, cicloalquiloC3-7-alquiloC0-8 o Ar-alquiloC0-8; U* y V* están ausentes o son CO, C(R'*)2, C=C(R15*)2, S(O)n*, O, NR15*, CR15'*OR15*, CR'*(OR''*)CR'*2, CR'*2CR'*(OR''*), C(O)C(R'*)2, C(R15*)2C(O), CONR15*, NR15*CO, OC(O), C(O)O, C(S)O, OC(S), C(S)NR15*, NR15*C(S), SO2NR15*, NR15*SO2, N=N, NR15*NR15*, NR15*C(R15*)2, NR15*C(R15*)2, C(R15*)2O, OC(R15*)2, G=C, CR15*=CR15*, Het, o Ar, con la condicion de que U* y V* no estén ausentes a la vez; W* es R'*R''N-, R'*R''*NR'*N-, R'*R''*NR'*NCO-, R'*2NR'*NC(=NR'*)-, R'*ONR'*C(=NR'*)-, o un grupo de formulas (4), W* es un grupo de formulas (5), Q* es NR'*, O o S; Ra* es H, alquilo C1-6, Ar-alquiloC0-6, Het-alquiloC0-6 o cicloalquilC3-6-alquiloC0-6, halogeno, OR1*, SR1*, COR1*, OH, N02, N(R1*)2, CO(NR1*)2, o CH2N(R1*)2; Rb* y Rc* se seleccionan independientemente entre el grupo que consiste en H, alquilo C1-6, Ar-alquiloC0-6, Het- alquiloC0-6 o cicloalquilC3-6-alquiloC0-6, halogeno, OR1*, SR1*, COR1*, OH, NO2, N(R1*)2, CO(NR1*)2, CH2N(R1*)2, o Rb* y Rc* se unen para formar un anillo aromático o no aromático de cinco o seis miembros, opcionalmente sustituido con halogeno, alquilo C1-4, OR1*, SR1*, COR1*, OH, NO2, N(R1*)2, CO(NR1*)2, CH2N(R1*)2, CN, o R''*R'*NC(=NR'*)-; X* es N=CR', C(O) u O; Y* está ausente, S u O; Z* es (CH2)t*, Het, Ar o cicloalquilo C3-7; M* es 1 o 2; N* es 0, 1, 2, o 3; q* es 0, 1, 2, o 3; r* es 0, 1 o 2; s* es 0, 1 o 2; t* es 0, 1 o 2; u* es 0, 1 o 2; v* es O o 1; y w* es 0 o 1; o una sal farmacéuticamente aceptable o un solvato del mismo. Formulacion correspondiente con 0,01 % a 50% p/p del compuesto de formula (1) o (2) y 5% a 99% de uno o más potenciadores de penetracion y ceras, pomadas o bases o combinaciones de las mismas, emolientes; antioxidantes y un tampon.Use of a vitronectin receptor antagonist for the preparation of a useful pharmaceutical formulation to inhibit excess scar formation on the skin of a mammal in need thereof by topical administration. Such skin has been cut, cracked, torn or injured during healing and excessive healing can be hypertrophic. Said antagonist is a compound of formula (1) or (2), wherein: R is H, C1-6 alkyl, Ar, Het or C1-6 alkylaryl; R1 is R7, A-C0-4 alkyl, A-C2-4 alkenyl, A-C2-4 alkynyl, A-C3-4 oxoalkenyl, A-C3-4 oxoalkynyl, C4-4-aminoalkyl or C3-4-aminoalkenyl 4, unsubstituted or substituted with any possible combination of one or more of R10 or R7; A is H, C3-6 cycloalkyl, Het or Ar; R7 is -COR8, -COCR'2R9, -C (S) R8, -S (O) mOR ', -S (O) mNR'R' ', -PO (OR'), -PO (OR ') 2 , -NO2, or tetrazolyl; each R8 is independently -OR ', -NR'R' '-NR'SO2R', -NR'OR 'or -OCR'2CO (O) R'; R9 is -OR ', -CN, -S (O) rR', -S (O) mN (R ') 2, -C (O) R', C (O) N (R) 2 or -CO2R ' ; R10 is H, halo, -OR11, -CN, -NR'R11, -NO2, -CF3, CF3S (O) r-, CO2R ', -CON (R') 2, A-alkylC0-6-, A- C1-6 oxoalkyl, A-C2-6- alkenyl, A-C2-6- alkynyl, A-C0-6- alkyloxy, A-C0-6- alkylamino or A-C0-6-S-alkyl (O) r-; R11 is R ', - C (O) R', -C (O) N (R ') 2, -C (O) OR', -S (O) mR 'or -S (O) mN (R') 2; R2 is a group of formulas (3), W is - (CHRg) a-U- (CHRg) b-; U is absent or is CO, CRg2, C (= CRg2), S (O) k, O, NRg, CRgORg, CRg (ORk) CRg2, CRg2CRg (ORk), C (O) CRg2, CRg2C (O), CONRi , NRiCO, OC (O), C (O) O, C (S) O, OC (S), C (S) NRg, NRgC (S), S (O) 2NRg, NRgS (O) 2, N = N, NRgNRg, NRgCRg2, CRg2NRg, CRg2O, OCRg2, C ::: C or CRg = CRg; G is NRe, S or O; Rg is H, C1-6 alkyl, Het-C0-6 alkyl, C3-7 cycloalkyl- C0-6 alkyl or Ar-C0-6 alkyl; Rk is Rg, -C (O) Rg, or -C (O) ORf; Ri is H, C1-6 alkyl, Het-C0-6 alkyl, C3-7 cycloalkyl, C0-6 alkyl, Ar-C0-6 alkyl or C1-6 alkyl substituted with one to three groups selected from the halogen-sewing group, CN, NRg2, ORg, SRg, CO2Rg, and CON (Rg) 2; Rf is H, C1-6 alkyl or Ar-C0-6 alkyl; Re is H, C1-6 alkyl, Ar-C0-6 alkyl, Het-C0-6 alkyl, C3-7 cycloalkyl-C0-6 alkyl or (CH2) kCO2Rg; Rb and Rc are independently selected from the group consisting of H, C1-6 alkyl, Ar-C0-6 alkyl, Het-C0-6 alkyl, C3-6 cycloalkyl-C0-6 alkyl, halogen, CF3, ORf, S (O) kRf , CORf, NO2, N (Rf) 2, CO (NRf) 2, and CH2N (Rf) 2, or Rb and Rc join to form a five or six-membered carbocyclic or heterocyclic, aromatic or non-aromatic ring, unsubstituted or substituted with up to three substituents selected from the group consisting of halogen, CF3, C1-4 alkyl, ORf, S (O) kRf, CORf, CO2Rf, OH, NO2, N (Rf) 2, CO (NRf) 2, CH2N (Rf) 2, and methylenedioxy; Q1, Q2, Q3 and Q4 are independently N or C-Ry, with the proviso that no more than Q1, Q2, Q3 and Q4 is N; R 'is H, C1-6 alkyl, Ar-C0-6 alkyl or C3-6 cycloalkyl-C0-6 alkyl; R '' is R ', -C (O) R' or -C (O) OR '; R '' 'is H, C1-6 alkyl, Ar-C0-6 alkyl, Het-C0-6 alkyl, C3-6 cycloalkyl- halogen, CF3, ORf, S (O) kRf, CORf, NO2, N ( Rf) 2, CO (NRf) 2, or CH2N (Rf) 2; Ry is H, halo, -OR9, -SRg, -CN, -NRgRk, -NO2, -CF3, CF3S (O) r-, CO2Rg, -COR9 or -CONRg2, or C1-6 alkyl unsubstituted or substituted with halo , -ORg, -SRg, - CN, -NRgR '', -NO2, -CF3, R'S (O) r-, - CO2Rg, -CORg or -CONRg2; a is 0, 1 or 2; b is 0, 1 or 2; k is 0, 1 or 2; m is 1 or 2; r is 0, 1 or 2; s is 0, 1 or 2; u is 0 or 1; and v is 0 or 1; or a compound of formula (2), wherein A1 is C or N; E is a five- or six-membered heteroaromatic ring or a six-membered aromatic ring unsubstituted or substituted with R3 * or R4 *; X1-X2 is CHR1 * -CH, CR1 * = C, NR1 * -CH, S (O) or * -CH or O-CH; X3 is CR5 * R5 '*, NR5 *, S (O) or * or O; R * is H, C1-6 alkyl, Ar, Het, C1-6 alkylaryl; R '' * is R '*, -C (O) R' * or - C (O) OR5 *; R '' * is C1-6 alkyl, C3-7 cycloalkyl-C0-4 alkyl or Ar-C0-4 alkyl; R1 * is H, C1-6 alkyl, C3-7 cycloalkylC0-4alkyl or ArC0-4alkyl; R2 * is -OR '*, -NR' * R '' *, -NR '* SO2R' '' *, -NROR '*, -OC (R' *) 2C (O) OR '*, -OC ( R '*) 2OC (O) -R' *, - OC (R '*) 2C (O) N (R' *) 2, CF3 or COC (R '*) 2R2' *; R2 '* is -OR' *, -CN, -S (O) r * R '*, S (O) 2N (R' *) 2, -C (O) R '*, C (O) N ( R '*) 2 or -CO2R' *; R5 * and R5 '* are independently H, C1-6 alkyl, C3-7 cycloalkyl-C0-4 alkyl or Ar-C0-4 alkyl; R6 * is W- (C (R '*) 2) q * -Z * - (CR' * R10 *) r * -U * - (C (R '*) 2) s * -V * - or W '* - (C (R' *) 2) q * -U * - (C (R '*) 2) s * -; R3 *, R4 * and R7 * are independently H, halo, -OR12 *, -SR12 *. -CN, -NR '* R12 *, -NO2, -CF3, CF3S (O) r * -, -CO2R' *, -CON (R1 *) 2, R14 * -alkylC0-6-, R14 * -oxoalkylC1- 6, R14 * -C2- 6- alkenyl, R14 * -C2-6 alkynyl, R14 * -C0-6 -alkyloxy, R14 * -CalkylaminoC0-6 or R14 * -C0-6 -alkyl (O) r * -; R8 * is R '*, C (O) R' *, CN, NO2, SO2R '* or C (O) OR5 *; R9 * is R '*, -CF3, -SR' *, or -OR '*; R1O * is H, C1-4 alkyl, or -NR '* R' '*; R12 * is R '*, -C (O) R' *, - C (O) N (R '*) 2, -C (O) OR5 *, -S (O) m * R' * or S ( O) 2N (R '*) 2; R14 * is H, C3-6 cycloalkyl, Het or Ar; R15 * is H, C1-10 alkyl, C3-7 cycloalkyl-C0-8 alkyl or Ar-C0-8 alkyl; U * and V * are absent or are CO, C (R '*) 2, C = C (R15 *) 2, S (O) n *, O, NR15 *, CR15' * OR15 *, CR '* ( OR '' *) CR '* 2, CR' * 2CR '* (OR' '*), C (O) C (R' *) 2, C (R15 *) 2C (O), CONR15 *, NR15 * CO, OC (O), C (O) O, C (S) O, OC (S), C (S) NR15 *, NR15 * C (S), SO2NR15 *, NR15 * SO2, N = N, NR15 * NR15 *, NR15 * C (R15 *) 2, NR15 * C (R15 *) 2, C (R15 *) 2O, OC (R15 *) 2, G = C, CR15 * = CR15 *, Het, or Ar , with the proviso that U * and V * are not absent at the same time; W * is R '* R''N-, R' * R '' * NR '* N-, R' * R '' * NR '* NCO-, R' * 2NR '* NC (= NR' * ) -, R '* ONR' * C (= NR '*) -, or a group of formulas (4), W * is a group of formulas (5), Q * is NR' *, O or S; Ra * is H, C1-6 alkyl, Ar-C0-6 alkyl, Het-C0-6 alkyl or C3-6 cycloalkyl, halogen, OR1 *, SR1 *, COR1 *, OH, N02, N (R1 *) 2, CO (NR1 *) 2, or CH2N (R1 *) 2; Rb * and Rc * are independently selected from the group consisting of H, C1-6 alkyl, Ar-C0-6 alkyl, Het-C0-6 alkyl or C3-6 cycloalkyl-halogen, OR1 *, SR1 *, COR1 *, OH, NO2, N (R1 *) 2, CO (NR1 *) 2, CH2N (R1 *) 2, or Rb * and Rc * join to form an aromatic or non-aromatic ring of five or six members, optionally halogen substituted, C1-4 alkyl, OR1 *, SR1 *, COR1 *, OH, NO2, N (R1 *) 2, CO (NR1 *) 2, CH2N (R1 *) 2, CN, or R '' * R '* NC (= NR' *) -; X * is N = CR ', C (O) or O; And * is absent, S or O; Z * is (CH2) t *, Het, Ar or C3-7 cycloalkyl; M * is 1 or 2; N * is 0, 1, 2, or 3; q * is 0, 1, 2, or 3; r * is 0, 1 or 2; s * is 0, 1 or 2; t * is 0, 1 or 2; u * is 0, 1 or 2; v * is O or 1; and w * is 0 or 1; or a pharmaceutically acceptable salt or solvate thereof. Corresponding formulation with 0.01% to 50% w / w of the compound of formula (1) or (2) and 5% to 99% of one or more penetration enhancers and waxes, ointments or bases or combinations thereof, emollients ; Antioxidants and a buffer.